That’s exactly what I mean. Do you think other
That’s exactly what I mean. Do you think other pharmaceutical companies would wait for some Mexican beaurocrat to do “their” part?
Let me tell you about color TV. Guillermo Gonzalez invented it. He went to the government. He went to the big industry types. They all laughed. He went to the USA.
Let me tell you about the contraceptive pill. The ball point pen. The reloading rifle. Indelible ink. Chewing gum. Chocolate. The list goes on.
Mexican beaurocrats are not the cream of the crop. You cannot expect them to do their part unless there is something in it for them. AMLO is trying to change that, but this is an age-old system based on cronyism and corruption.
Did NP offer first dibs on LL? Did he offer a better price? He said on a CC that a foundation would have to make it available to other countries that could not afford it.
I am not at all surprised that having 350 combo data ready 2 years ago, NP did not apply to U.K or other countries until now because meds are 30-40% less there. He wants the whole enchilada. It does seem more logical though to have applied before instead of doing Iliad deals. Just my opinion
For this reason AMLO wants to buy meds from other parts of the world instead of American BPs. He’s been buying from France and China at a “deep discount”. I never follow politics, but I’ve read a few headlines about this too in the USA.
1
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Russel Metals Inc. Reports Third Quarter Results for 2025 Russel Metals Inc. (TSX:RUS) has recently shared its financial performance for the three-month period ending September 30, 2025. The results reflect a positive trajectory in revenue and strategic initiatives to enhance its market position. Key Financial Metrics Overview In this quarter, Russel Metals has...
Continue Reading
KBC Group's Capital Position Remains Strong KBC Group has reported a robust standing in its capital levels, significantly exceeding the minimum capital requirements mandated by the European Central Bank (ECB). As part of the Supervisory Review and Evaluation Process (SREP) scheduled for the upcoming year, KBC received formal notification regarding its capital metrics....
Continue Reading
Synlogic Provides Third Quarter 2024 Financial Results Synlogic, Inc. (NASDAQ: SYBX), a prominent biopharmaceutical firm dedicated to developing innovative therapeutics for serious diseases, has recently outlined its financial performance for the third quarter of 2024. The organization is actively working on advancing its mission to enhance healthcare through...
Continue Reading
Incannex Healthcare's Remarkable Financial Progress Incannex Healthcare Inc. (NASDAQ: IXHL) is making impressive strides in the biopharmaceutical world, focusing on breakthrough treatments for chronic diseases. Their recent fiscal year report outlines not only financial outcomes but also a plethora of operational and clinical advancements aimed at addressing significant...
Continue Reading
Alpha Liquid Terminal Introduces ChatAnalyst Financial Agent Recently, a game-changing tool was launched that promises to redefine how individuals manage and interpret financial data. This is powered by the innovative company, Alpha Liquid Terminal. The newly unveiled AI-driven financial analyst agent, known as ChatAnalyst, is designed to simplify and streamline financial...
Continue Reading